ABBV News & Events

AbbVie announced a multi-year partnership with Major League Baseball, naming AbbVie the Official Pharmaceutical Partner of MLB beginning with the 2026 season. This partnership, a first-of-its-kind for the company, marks the national expansion of Striking Out Cancer - first introduced during the 2025 MLB season through AbbVie's collaboration with the Chicago Cubs, which enters its second year in the 2026 season. This new partnership extends Striking Out Cancer beyond AbbVie's hometown of Chicago to become a league-wide initiative. Throughout the MLB season, AbbVie will donate $20 for every strikeout, up to a maximum donation of $1M per season. This per-strikeout contribution reflects the 20% of the population worldwide who will be diagnosed with cancer before age 75, according to the World Health Organization's Global Cancer Observatory.

Alloy Therapeutics announced an agreement with AbbVie to develop a new antibody platform to discover potent, specific, and effective antibodies against targets that are difficult to address with current technologies. As part of the multi-year agreement, Alloy will receive an upfront payment, as well as an additional payment in connection with the delivery of the platform to AbbVie. The collaboration provides AbbVie with access to the antibody discovery platform as part of its broader research efforts. For Alloy, the collaboration reflects its continued focus on enabling partners through platform-based discovery technologies and reinforces its commitment to advancing antibody therapeutics.

Allergan Aesthetics, an AbbVie company, announced the launch of the Skin Quality Index. "The framework is supported by the most comprehensive global research to date published in Dermatologic Surgery, which identified inconsistencies in terminology used by patients and providers, and highlighted the need for clearer, more consistent language during aesthetic consultations," the company said.